BACE1 Inhibition Using 2'-OMePS Steric Blocking Antisense Oligonucleotides.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Amyloid beta-peptide is implicated in Alzheimer's disease pathogenesis.
• Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme in amyloid beta-peptide production.
• Inhibiting BACE1 may offer a therapeutic strategy for Alzheimer's disease.

Purpose of the Study:

• To develop and evaluate a novel antisense oligonucleotide (AO) for downregulating BACE1.
• To assess the efficacy of the AO in reducing BACE1 RNA and protein levels.
• To explore the potential of AO as a preventative therapeutic for Alzheimer's disease.

Main Methods:

• Design and synthesis of 2'-O-Methyl modified antisense oligonucleotides with phosphorothioate backbone.
• Evaluation of AO efficacy in downregulating BACE1 RNA expression.
• Assessment of BACE1 protein level reduction.
• Comparison with phosphorodiamidate morpholino chemistry variants.

Main Results:

• One AO variant, AO2 targeting exon 2, demonstrated significant downregulation of BACE1 RNA by 90%.
• AO2 also reduced BACE1 protein levels by 45%.
• Phosphorodiamidate morpholino chemistry variants were less effective than the 2'-O-Methyl phosphorothioate backbone variant.

Conclusions:

• The developed AO, specifically AO2, is a potent inhibitor of BACE1.
• AO2 demonstrates potential as a preventative therapeutic strategy for Alzheimer's disease.
• Further research into AO-based therapies for Alzheimer's disease is warranted.